Literature DB >> 2099429

Concomitant euthyroid Graves' ophthalmopathy and isolated ocular myasthenia gravis.

H Raef1, M Ladinsky, R Arem.   

Abstract

A 44 year old diabetic woman presented with diplopia and bilateral ptosis and mild exophthalmos. The patient was clinically euthyroid, the baseline thyroid function tests were normal, but the thyroid stimulating hormone response to thyrotrophin releasing hormone was flat. Computed tomographic scan and magnetic resonance imaging of the orbits showed left medial and inferior rectus muscle thickening, more prominent on the left side, consistent with Graves' disease. The tensilon stimulation test resulted in resolution of the ptosis and partial improvement of the ophthalmoplegia. The single fibre electromyography was consistent with a defect in neuromuscular transmission. However, forced duction test was normal and anti-acetylcholine receptor antibodies were undetectable. Significant improvement of the extraocular muscle function and resolution of the right ptosis had resulted from anticholinesterase therapy. These findings and the clinical response to therapy were consistent with concomitant euthyroid Graves' ophthalmopathy and ocular myasthenia gravis. Coexistent isolated ocular myasthenia gravis and Graves' ophthalmopathy is rare and should be considered in patients with findings of ocular myasthenia and extraocular muscle dysfunction.

Entities:  

Mesh:

Year:  1990        PMID: 2099429      PMCID: PMC2429728          DOI: 10.1136/pgmj.66.780.849

Source DB:  PubMed          Journal:  Postgrad Med J        ISSN: 0032-5473            Impact factor:   2.401


  13 in total

1.  Studies on thyrotrophin receptor antibodies in patients with euthyroid Graves' disease.

Authors:  K Kasagi; H Hatabu; Y Tokuda; Y Iida; K Endo; J Konishi
Journal:  Clin Endocrinol (Oxf)       Date:  1988-10       Impact factor: 3.478

2.  Changes in thyroid functions in patients with euthyroid Graves' disease.

Authors:  H Tamai; T Nakagawa; N Ohsako; O Fukino; H Takahashi; F Matsuzuka; K Kuma; S Nagataki
Journal:  J Clin Endocrinol Metab       Date:  1980-01       Impact factor: 5.958

3.  Identification of subgroups of euthyroid graves's ophthalmopathy.

Authors:  D H Solomon; I J Chopra; U Chopra; F J Smith
Journal:  N Engl J Med       Date:  1977-01-27       Impact factor: 91.245

4.  The ocular signs and symptoms of myasthenia gravis.

Authors:  H J Oosterhuis
Journal:  Doc Ophthalmol       Date:  1982-01-29       Impact factor: 2.379

5.  Autoimmunity in ocular and generalised myasthenia gravis.

Authors:  M J Garlepp; R L Dawkins; F T Christiansen; J Lawton; G Luciani; J McLeod; J Bradley; G Genkins; C S Teng
Journal:  J Neuroimmunol       Date:  1981-09       Impact factor: 3.478

6.  Graves' ophthalmopathy, ocular myasthenia gravis and Hashimoto's thyroiditis.

Authors:  H Czernobilsky; R Ziegler
Journal:  Isr J Med Sci       Date:  1985-04

7.  Demonstration of a circulating autoantibody against a soluble eye-muscle antigen in Graves' ophthalmopathy.

Authors:  K Kodama; H Sikorska; P Bandy-Dafoe; R Bayly; J R Wall
Journal:  Lancet       Date:  1982-12-18       Impact factor: 79.321

8.  Anti-muscle antibodies in Graves' ophthalmopathy.

Authors:  M Kadlubowski; W J Irvine; A C Rowland
Journal:  J Clin Lab Immunol       Date:  1987-11

9.  Myasthenia gravis and HLA antigens in American blacks and other races.

Authors:  F T Christiansen; M S Pollack; M J Garlepp; R L Dawkins
Journal:  J Neuroimmunol       Date:  1984-12       Impact factor: 3.478

10.  Circulating TSH-binding inhibiting immunoglobulins in myasthenia gravis.

Authors:  W R Kiessling; R Finke; P Kotulla; H Schleusener
Journal:  Acta Endocrinol (Copenh)       Date:  1982-09
View more
  1 in total

1.  A data-driven approach for the discovery of biomarkers associated with thyroid eye disease.

Authors:  Huihui Zou; Weiwei Xu; Ying Wang; Zhihong Wang
Journal:  BMC Ophthalmol       Date:  2021-04-09       Impact factor: 2.209

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.